Immunome’s (IMNM) “Outperform” Rating Reaffirmed at Wedbush

Immunome (NASDAQ:IMNMGet Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at Wedbush in a research note issued on Tuesday, RTT News reports. They currently have a $33.00 price target on the stock. Wedbush’s price target would suggest a potential upside of 124.49% from the company’s previous close.

IMNM has been the topic of a number of other research reports. Leerink Partnrs restated an “outperform” rating on shares of Immunome in a research report on Monday, January 29th. Guggenheim started coverage on shares of Immunome in a report on Monday, April 15th. They set a “buy” rating and a $35.00 price target on the stock. JPMorgan Chase & Co. assumed coverage on shares of Immunome in a research report on Tuesday, April 30th. They issued an “overweight” rating and a $24.00 target price on the stock. Finally, SVB Leerink initiated coverage on Immunome in a research note on Monday, January 29th. They issued an “outperform” rating and a $30.00 price target for the company. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $30.50.

Get Our Latest Report on IMNM

Immunome Stock Performance

IMNM traded down $0.91 on Tuesday, hitting $14.70. 981,887 shares of the company were exchanged, compared to its average volume of 731,483. The stock’s fifty day moving average is $19.98 and its 200-day moving average is $15.70. Immunome has a 12 month low of $4.50 and a 12 month high of $30.96. The company has a market cap of $881.12 million, a PE ratio of -2.68 and a beta of 1.87.

Immunome (NASDAQ:IMNMGet Free Report) last announced its quarterly earnings results on Thursday, March 28th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.26). The firm had revenue of $3.83 million during the quarter, compared to analyst estimates of $3.40 million. Immunome had a negative net margin of 761.92% and a negative return on equity of 69.74%. As a group, equities research analysts expect that Immunome will post -1.91 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Dorsey Wright & Associates purchased a new position in Immunome during the third quarter valued at $26,000. Jump Financial LLC purchased a new position in shares of Immunome during the 4th quarter valued at about $172,000. Acadian Asset Management LLC bought a new stake in Immunome during the 3rd quarter worth approximately $414,000. Sei Investments Co. purchased a new position in Immunome during the first quarter valued at approximately $469,000. Finally, Clear Creek Financial Management LLC bought a new position in shares of Immunome in the first quarter worth approximately $547,000. Institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

(Get Free Report)

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.

Featured Stories

Analyst Recommendations for Immunome (NASDAQ:IMNM)

Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.